Skip to main content
2025 ASCRS Annual Scientific Meeting Main banner
Final Program


Visit ASCRS U
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Self-Assessment
Self-Assessment
Social
Social
Industry
Industry
Back

Session: Late Breaking Abstracts (NON-CME)

LB4 - Total Neoadjuvant Therapy With mFOLFOX6 Plus Bevacizumab and Short-course Radiotherapy for Ras-mutant, High-risk Locally Advanced Rectal Cancer: The TRAINER Trial

Monday, May 12, 2025
8:30 AM – 8:38 AM PT
Location: Ballroom 6B, Upper Level

    Presenting Author(s)

  • Bo Feng (he/him/his)

    MD, PhD
    Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai, China (People's Republic)

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

    • Author(s)

  • JL

    Jingyi Liu, n/a

    MD
    Ruijin Hospital
    Shanghai, Shanghai, China (People's Republic)

    Disclosure information not submitted.

  • ZC

    Zhenghao Cai, n/a

    MD, PhD
    Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai, China (People's Republic)

    Disclosure information not submitted.

  • TM

    Tao Ma, n/a

    Md
    Ruijin Hospital
    Shanghai, Shanghai, China (People's Republic)

    Disclosure information not submitted.

  • GC

    Gang Cai, n/a

    MD
    Ruijin Hospital
    Shanghai, Shanghai, China (People's Republic)

    Disclosure information not submitted.

All of the relevant financial relationships listed below have been mitigated.
Bo Feng: This individual has no financial relationships with ineligible companies.
Image or Table (Do Not add text here):

Purpose/Background: Total neoadjuvant therapy (TNT) intensified by targeted therapy might improve local and systemic control for high-risk locally advanced rectal cancer (LARC). Our study aimed to explore the efficacy and safety of a modified FOLFOX6 (mFOLFOX6)-based TNT regimen plus bevacizumab in Ras-mutant high-risk LARC patients.

Methods/Interventions: TRAINER-B was a single-arm, phase II trial, enrolling RAS-mutant LARC patients with at least one high-risk factor (cT3c-4, cN2, mesorectal fascia involvement, lateral lymph node involvement, and/or extramural venous involvement) between April 2021 and March 2024. Data were analyzed between August 2024 and November 2024. Four cycles of mFOLFOX6 plus bevacizumab were administered as induction chemotherapy, followed by SCRT (25Gy/5Fx) and two cycles of mFOLFOX6 as consolidation chemotherapy. Surgery was planned 8 weeks after completion of radiotherapy. After surgery, high-risk stage III patients (ypT4 or ypN2) were recommended to receive an extra six cycles of mFOLFOX6 as adjuvant chemotherapy. Patients with clinical complete response (cCR) were allowed to choose the “Watch & Wait” (W&W) strategy. The primary endpoint was the complete response (CR) rate. The secondary endpoints included patient compliance and safety, pathological outcomes, and survival data.

Results/Outcomes: Of 47 patients analyzed, 17 (36.2%) were female, and the median (IQR) age was 59 (51-68) years. The CR was achieved in 18 (38.3%) patients, including 14 (29.8%) pCR and four (8.5%) cCR. The prevalence of grade III toxicities was 34.0% whereas no grade IV-V toxicity was observed. 43 patients underwent curative surgery, and sphincter preservation was accomplished in 39 (90.7%) patients. Seven patients (16.3%) experienced Clavian-Dindo I-II postoperative complications, including four (9.3%) anastomotic leaks.

Conclusion/Discussion: The intensified TNT regimen plus bevacizumab achieved a satisfactory CR rate with acceptable toxicities and complications for RAS-mutant high-risk LARC patients. Long-term survival data are needed to validate the efficacy of this regimen.